Category: Press Release

Social Media

Geistlich Announces Exciting Product Line Extension from Reoss: Yxoss CBR® Fully Protect

April 9, 2024

Geistlich Pharma North America announced today the launch of Reoss’s latest innovation, Yxoss CBR® Fully Protect, the newest addition to the Yxoss CBR® Family!

Now there are three Yxoss CBR® options to best suit your needs: Yxoss CBR® Classic, Yxoss CBR® Protect, and now Yxoss CBR® Fully Protect! The new Yxoss CBR® Fully Protect has the same characteristics as the other configurations: 3D-printed custom-made titanium mesh that accurately reflects specific patient data, provides a solution for both vertical and horizontal ridge augmentation procedures, and gives the opportunity for integrated implant positioning.

In addition, Yxoss CBR® Fully Protect maintains the same established benefits of the Yxoss CBR® family: removes time-consuming, cutting, shaping, and adapting titanium mesh, gives the opportunity to reduce surgery time due to perfect fit without complex adaptations, and eliminates sharp edges and challenging removal which inhibits proper healing. The easy removal design allows for all Yxoss CBR® products to be removed easily with pre-defined breaking points.

For complex bone defects, needs will vary based on the position and extent of the defect, the patient’s anatomy, overall treatment requirements, and personal preference. The benefit of Yxoss CBR® Fully Protect is its fully microstructured surface that protects from tissue ingrowth. Having a dense microstructure across the complete scaffold allows for high stability and space maintenance, very easy removal, and enables good bone maturation due to a very well-vascularized tissue.

For more information about Yxoss CBR® Fully Protect and to stay updated on the latest news and offers from Geistlich, please visit https://geistlich.us/

Geistlich Pharma North America announced today the launch of Reoss’s latest innovation, Yxoss CBR® Fully Protect, the newest addition to the Yxoss CBR® Family!

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

References

Righesso, L A R et al. “Dynamic contrast-enhanced magnetic resonance imaging for monitoring neovascularization during bone regeneration-a randomized in vivo study in rabbits.” Clinical oral investigations vol. 25,10 (2021): 5843-5854. doi:10.1007/s00784-021-03889-6
Zaffe, Davide, and Ferdinando D’Avenia. “A novel bone scraper for intraoral harvesting: a device for filling small bone defects.” Clinical oral implants research vol. 18,4 (2007): 525-33. doi:10.1111/j.1600-0501.2007.01368

Geistlich Unveils Exciting Product Line Expansion: Introducing the SafeScraper TWIST VOLUMIZER

March 20, 2024

Geistlich Pharma North America announced today the launch of its latest innovation with META, the SafeScraper TWIST VOLUMIZER, the newest addition to the SafeScraper Family!

The new SafeScraper Twist VOLUMIZER provides the established benefits of the proven SAFESCRAPER TWIST curve: it provides an easy method for harvesting autogenous cortical bone for use in grafted sites with a minimally invasive technique.

Due to the exceptional functionality of the instrument, the ergonomic design provides excellent control during the harvesting procedure. The curved tip of the instrument facilitates easy access to donor sites, which makes it ideal for both minor and major harvesting procedures.

The SafeScraper Twist VOLUMIZER is the extra volume version of the SafeScraper Twist; it offers the same performance of rapid and accurate collection of autologous cortical bone, while collecting a larger bone volume.

This product has a redesigned blade with double grooves that allow for three collecting surfaces. The cutting performance reduces patient discomfort, and the quality of harvested bone for use in grafted sites promotes graft acceptance, neovascularization, and bone regeneration. ^1,2

For more information about the SafeScraper TWIST VOLUMIZER and to stay updated on the latest news and offers from Geistlich, please visit https://geistlich.us/

Geistlich Pharma North America announced today the launch of its latest innovation with META, the SafeScraper TWIST VOLUMIZER, the newest addition to the SafeScraper Family!

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

References

Righesso, L A R et al. “Dynamic contrast-enhanced magnetic resonance imaging for monitoring neovascularization during bone regeneration-a randomized in vivo study in rabbits.” Clinical oral investigations vol. 25,10 (2021): 5843-5854. doi:10.1007/s00784-021-03889-6
Zaffe, Davide, and Ferdinando D’Avenia. “A novel bone scraper for intraoral harvesting: a device for filling small bone defects.” Clinical oral implants research vol. 18,4 (2007): 525-33. doi:10.1111/j.1600-0501.2007.01368

Celebrating Innovation and Legacy: Geistlich Pharma’s 11th Annual Philip J. Boyne Scholarship Award

December 07, 2023

Geistlich Pharma North America, Inc. proudly announces the successful conclusion of the 11th annual Philip J. Boyne Scholarship Award. This prestigious scholarship, born out of the shared enthusiasm for innovation and bone regeneration between Dr. Philip J. Boyne and Dr. Peter Geistlich, continues to make a lasting impact on the field. The scholarship, established to honor the memory and collaborative spirit of these two pioneers, recognizes and supports residents who embody their commitment to advancing oral and maxillofacial surgery.

Honoring a Legacy:

The friendship between Dr. Philip J. Boyne and Dr. Peter Geistlich laid the foundation for groundbreaking developments in the field, culminating in the creation of Geistlich Bio-Oss®. To pay tribute to their enduring legacy, Geistlich Pharma North America, Inc. established the Philip J. Boyne Scholarship, an initiative that serves as a beacon for aspiring professionals who share the same spirit of innovation.

A Decade of Support and Empowerment:

Since its inception in 2011, the Philip J. Boyne Scholarship has empowered hundreds of residents from Oral and Maxillofacial Surgery (OMS) Programs across the country. These aspiring professionals have been given the invaluable opportunity to participate in the AAOMS Dental Implant Conference held annually in Chicago. This exposure to cutting-edge research, techniques, and networking has played a role in shaping the future of oral and maxillofacial surgery.

Commitment to Excellence:

This year, the commitment to excellence and the advancement of the field reached new heights, with scholarships awarded to 40 residents. Geistlich Pharma North America, Inc. continues to demonstrate its dedication to fostering the next generation of leaders and innovators.

Recognition and Celebration:

The culmination of this year’s scholarship program was celebrated at the annual cocktail reception on November 30, 2023, at the Sheraton Grand Hotel, Chicago, coinciding with the AAOMS Dental Implant Conference. This event provided a platform to recognize the outstanding achievements of the scholarship recipients, creating an atmosphere of camaraderie and collaboration among professionals in the field.

Geistlich Pharma North America, Inc. remains at the forefront of advancing oral and maxillofacial surgery through its commitment to innovation and education. The Philip J. Boyne Scholarship stands as a testament to the company’s dedication to nurturing the talents and aspirations of the next generation, ensuring a legacy of excellence in the ever-evolving field of oral and maxillofacial surgery.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.

Diego Gabathuler becomes the new CEO of Geistlich

December 01, 2023

Geistlich Pharma AG has appointed Diego Gabathuler as its new CEO, effective December 1, 2023. He succeeds Ralf Halbach, who departed the company in August 2023.

Diego Gabathuler is a 49-year-old Swiss National who brings a broad range of experience from various management positions as well as extensive knowledge in business development and strategic marketing.

Most recently, he was CEO of the dental company Ivoclar. He has expertise in the MedTech sector, excellent leadership qualities, and a proven strategic acumen. His professional career also includes management positions at international digital-tech companies such as Logitech, Activision, and Electronic Arts.

Andreas Geistlich, Chairman of the Board of Directors, who held the CEO position on an interim basis: “The Geistlich strategic plan includes further investment in new products, solutions, and technologies in order to apply regenerative medicine in helping even more people around the world. We are convinced that Diego Gabathuler’s expertise will support us significantly in this mission.”

Geistlich wishes Diego a successful start, and we look forward to working with him to further advance the future of regenerative medicine.

Geistlich appoints Diego Gabathuler as new CEO. As a proven leader, he brings many years of experience in the MedTech industry and will continue to drive the company’s expansion strategy in regenerative medicine.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.

Geistlich Pharma AG Executive Chairman, Dr. Andreas Geistlich, Honored with AAOMS Special Citation Award

For Immediate Release:

PRINCETON, N.J. October 2, 2023 – Geistlich Pharma North America Inc. is pleased to announce that our Executive Chairman, Dr. Andreas Geistlich, has been awarded the prestigious American Association of Oral and Maxillofacial Surgeons (AAOMS) Board of Trustees Special Citation Award for the company’s exceptional and longstanding contributions to the field of Oral and Maxillofacial Surgery.

“Dr. Geistlich, the Geistlich Family and Geistlich Pharma AG are all prominent supporters of AAOMS and our larger specialty. In 2013, Dr. Peter Geistlich founded the Osteo Science Foundation with the mission of further innovating the use of regenerative medicine within oral and maxillofacial surgery and improving patient care. Now celebrating its 10th anniversary, Osteo Science has contributed over $3 million toward oral and maxillofacial research,” said American Association of Oral and Maxillofacial Surgeons. “For Dr. Geistlich’s ongoing support to the betterment of the specialty, we present him with the Board of Trustees Special Citation Award.”

“It is a great honor for us to celebrate Osteo Science Foundation’s 10th Anniversary at the 105th AAOMS Annual Meeting. We are especially proud to have Dr. Andreas Geistlich recognized by AAOMS with a Special Citation during the Opening Ceremony this year. Osteo Science Foundation succeeds because of the valuable partnership with Dr. Geistlich and his family, with Geistlich Pharma, and with the leadership and membership of AAOMS,” stated Paul Tiwana, DDS, MD, FACS, FACD, Chair, Osteo Science Foundation.

The Special Citation Award was presented to Dr. Andreas Geistlich, at the 105th Annual AAOMS Meeting Opening Awards Ceremony on September 20, 2023, in San Diego, CA. The event brought together leaders, professionals, and enthusiasts from the Oral and Maxillofacial community to celebrate his remarkable achievements and contributions.

The AAOMS Board of Trustees Special Citation Award is a testament to the dedication, impact, and unwavering commitment of Geistlich to the OMS community. Geistlich extends its heartfelt congratulations to Dr. Geistlich on receiving this award.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

Social Media

https://www.lynchbiologics.com/

iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.

Geistlich announces the dramatic expansion of their allograft portfolio – vallos^® sets the pace for regeneration

PRINCETON, N.J., March 16, 2023 /PRNewswire/ – Geistlich Pharma North America Inc. is pleased to introduce a growing variety of vallos^® allograft configurations to increase treatment flexibility through its partnership with a world-leading allograft provider.

This expanded Geistlich Select product line brings an added confidence to regenerative procedures with:

A full portfolio of 35 variations includes granules, fibers, demineralized, mineralized, and blended allografts
A single source supplier that ensures consistent product quality¹
Cortico-cancellous bone which is known to provide a natural scaffold for cell attachment and infiltration²
Stringent donor selection and proprietary aseptic processing that protects the native integrity of the graft

With multiple sizes and configurations available, the vallos^® allograft line allows clinicians to choose exactly what they need for each procedure. For smaller routine defects, vallos^® granules are ideal, while vallos^®f fibers are designed for larger, more complex defects.

“We are thrilled to introduce our new partner MTF Biologics – together we share a passion for regeneration, scientific advancement, and a commitment to quality. Our combined values and dedication to patient care makes this an outstanding collaboration. We look forward to a long and successful partnership.”
Les Burrows, General Manager of Geistlich Pharma North America.

vallos™

Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Our expanded vallos^® and vallos^®f portfolio bring clinicians even more options to enhance their ability to manage a variety of clinical indications and we are proud that Geistlich is now the company of choice for all their bone substitute needs.

About MTF Biologics^® – MTF Biologics® is a physician-led non-profit organization with 35 years of experience, dedicated to providing clinically sound and safe allograft tissue. The company has the largest recovery network and the most stringent donor screening in the industry, with less than 2% of all donated tissue accepted.¹MTF Biologics^® is the only tissue bank that utilizes The Vanguard Method^™ for quantitative and qualitative tissue testing and analysis – exceeding industry standards. All tissues are 100% aseptically processed, which avoids the use of harsh chemicals that can compromise the integrity of the tissue. MTF Biologics^® advances the science of tissue transplantation by awarding grants that fund groundbreaking research and is proud to support researchers and clinicians throughout their careers.

About Geistlich Pharma North America Inc. – With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products. This begins with our world-class bone substitute Geistlich Bio-Oss^® and Geistlich vallomix™ the first allograft/xenograft bone substitute. Resorbable collagen membrane Geistlich Bio-Gide^® extends its reach with Geistlich Bio-Gide^® Compressed for an alternative handling experience. Our collagen matrix Geistlich Mucograft^® is ideal for soft-tissue regeneration, and our volume-stable collagen matrix breakthrough Geistlich Fibro-Gide^® providing an alternative to connective tissue grafts. Finally, our GEM 21S^®, growth-factor enhanced matrix, is engineered to stimulate wound healing and bone regeneration. Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
902 Carnegie Center, Suite 360
Princeton, NJ 08540 USA

Home Page:
https://geistlich.us
LinkedIn
Instagram
Facebook

Contact:
Ron Frezel: [email protected]

Data on file, MTF Biologics^®
Roberts TT and Rosenbaum AI. Bone grafts, bone substitutes and orthobiologics; The bridge between basic science and clinical advancements in fracture healing. 2012.Organogenesis 8 (114-124)

Geistlich unveils vallos™ – a new demineralized allograft that sets the pace for regeneration

For Immediate Release:

Princeton, New Jersey November 7, 2022: Geistlich Pharma North America Inc. is setting the pace for expanded treatment options with the introduction of vallos™, our first demineralized allograft.

With two formulations for treatment flexibility, vallos™ granules are ideally suited for smaller routine defects while vallos™f fibers are designed for larger more complex defects. This Geistlich Select product line brings an added confidence to regenerative procedures, with:

Verified osteoinductive potential in every lot¹
Consistent product quality¹
Proven regenerative capacity by exhibiting all five elements of bone formation¹
Vital bone after 18-20 weeks²

“We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family.”
Les Burrows, General Manager of Geistlich Pharma North America.

vallos™

Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Demineralized vallos™ and vallos™f offer clinicians more options to enhance their ability to manage a variety of clinical indications and are the first products to become part of the Geistlich Select family.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products. This begins with our world-class bone substitute Geistlich Bio-Oss® and its full line of sizes and formulations. Resorbable collagen membrane Geistlich Bio-Gide® extends its reach with two new products: Geistlich Bio-Gide® Compressed for an alternative handling experience; and uniquely pre-cut Geistlich Bio-Gide® Shape designed for the treatment of non-intact extraction sockets. Finally, our collagen matrix Geistlich Mucograft® is ideal for soft-tissue regeneration, and our volume-stable collagen matrix breakthrough Geistlich Fibro-Gide® providing an alternative to connective tissue grafts.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Exactly Like No Other. To learn more about Geistlich, please visit us on our website https://dental.geistlich-na.com, or connect and follow us on LinkedIn, Instagram and Facebook.

Media Contact:

For more information on vallos™ and vallos™f, please visit: https://vallos.geistlich-na.com Or contact Ron Frezel at: [email protected]

Geistlich Pharma North America Inc.
902 Carnegie Center, Suite 360
Princeton, NJ 08540 USA

Home Page:
https://dental.geistlich-na.com
https://www.lynchbiologics.com/
LinkedIn
Instagram
Facebook

Contact:
Ron Frezel: [email protected]

Data on file, DCI Donor Services Tissue Bank
Robert A Wood & Brian L Mealey: J Periodontol. 2012 Mar;83(3):329-36. (Clinical Study)

Geistlich Pharma North America, Inc. acquires Lynch Biologics, LLC, a biologics and tissue engineering company

For Immediate Release:

Princeton, New Jersey October 26, 2022: Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer, and sole provider of GEM 21S^®, the first recombinant growth factor product for use in oral regenerative surgery. This acquisition further strengthens the regenerative product portfolio of Geistlich and provides significant growth potential.

“I am so excited to combine Lynch Biologics with Geistlich Pharma North America. We look forward to being a part of the Geistlich Pharma North America team, known for their tremendous professionalism, integrity, and commitment to improving care for patients,” stated Sam Lynch, DMD, DMSC, CEO, Lynch Biologics. “I believe this is an exciting opportunity as we bring together the companies with the widely used biologic and the world market leader in dental biomaterials, which is an ideal combination to serve our customers in the oral regenerative space. Equally, I am thrilled to expand our training and education capabilities, as well as continue our clinical research. Having played a small role in helping to launch Geistlich products in the US many years ago and now having the ability years later to work with this team to bring new cutting-edge technologies together is incredibly fulfilling for me personally.”

“We are delighted to welcome Lynch Biologics to our Geistlich family and to have the opportunity to work with Dr. Lynch and his talented team that are so passionate and committed to developing products that make a difference in the field of regeneration. I couldn’t be more excited about our future together,” said Les Burrows, General Manager, Geistlich Pharma North America. “GEM 21S augments our expanding portfolio of regenerative solutions. This acquisition allows us to align with another organization that has the same beliefs, clinically proven products, and a commitment to ongoing research. This sets the stage for additional new products that support our mission to drive regeneration in oral surgery.”

“The acquisition of Lynch Biologics demonstrates our commitment to the clinicians and patients of the United States and further enhances our portfolio of innovative products used worldwide, said Dr. Ralf P. Halbach, Chief Executive Officer, Geistlich Pharma AG. “We have long admired the pioneering spirit of Dr. Sam Lynch and welcome Lynch Biologics into our family.”

Following the close of this acquisition, as a member of the Geistlich team Dr. Lynch will continue to support Lynch Biologic customers through best-in-class dental education and trainings, as well as assist in addressing any questions doctors may have regarding GEM 21S®. In addition, we’re seamlessly integrating our operations, so all of Lynch Biologic customers can continue to order GEM 21S® online, call the same 1-800 number, and most importantly, continue to get the same personalized service.

The combination of two regenerative leaders offers:

Expanded regenerative solutions for clinicians and their patients
A combined team of purpose-driven leaders and highly skilled experts
Strengthened product development, clinical research, and education on new regenerative technologies
A shared commitment to research, quality, and safety

About Lynch Biologics

Lynch Biologics is a regenerative medicine and tissue engineering company supplying advanced biotechnology products that promote healing and tissue regeneration spearheaded by GEM 21S®, and other widely used regenerative products, for periodontal and oral and maxillofacial indications. Their products have been used to help millions of patients regenerate lost bone and soft tissues and continue to be among the most popular grafting products with our dental colleagues.

GEM 21S® Growth-factor Enhanced Matrix was developed utilizing innovative tissue engineering principles which combine a bioactive protein (highly purified recombinant human platelet-derived growth factor, rhPDGF-BB) with an osteoconductive matrix (beta tricalcium phosphate, β-TCP).

This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.

About Geistlich North America Inc.

Geistlich Pharma North America brings the leader in regenerative dentistry directly to the United States and Canada. For 171 years, our respected family-owned Swiss parent company, Geistlich Pharma AG, has pioneered technological advances that make regenerative treatment with safe and naturally sourced biomaterials the preferred choice for clinical predictability.

Geistlich is the world market leader in regenerative dentistry^1,2. All our products are investigated rigorously before being released on the market. Geistlich products have been tested and developed for use in various therapeutic areas in collaboration with more than 100 universities and leading surgeons.

We consistently meet or exceed industry safety and quality standards and follow a continuous training program for our employees. Meeting international scientific standards is a core principle of Geistlich Biomaterials. Geistlich Bio-Oss® and Geistlich Bio-Gide® bone regeneration materials are the most researched products in regenerative dentistry worldwide^1,2.

Moreover, we are committed to guiding clinicians through regenerative education, whether through physical courses, webinars, or through our BIOBRIEF clinical case series.

These substantial efforts lead to a single goal – to provide the highest standard of product quality and safety in order to improve the patient’s quality of life.

Geistlich Pharma North America Inc.

400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:

https://geislich.us